OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	76
The endosomal-lysosomal system in ADC design and cancer therapy	59
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	56
Aflibercept biosimilars – so near, yet so far	55
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	45
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	42
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	34
Antibody drug conjugates for glioblastoma: current progress towards clinical use	33
Biosimilars and access to biologic therapy in immune-mediated diseases	32
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?	30
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	29
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	29
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	28
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	27
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	26
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	26
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas	26
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	26
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies	25
Long-acting delivery and therapies for neovascular age-related macular degeneration	25
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	24
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials	23
Signaling new therapeutic opportunities: cytokines in prostate cancer	23
Correction	23
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	22

Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	22
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	21
New biological agents in systemic lupus erythematosus	21
Correction	21
Unmet needs in cervical cancer – can biological therapies plug the gap?	21
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	21
An evaluation of guselkumab for the treatment of ulcerative colitis	21
Correction	21
Cell population data as predictive biomarkers for biologic therapy response in psoriasis	21
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	19
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	19
Relapses in giant cell arteritis: challenges after discontinuation of targeted therapies	19
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer	19
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Strategies for extending the half-life of biotherapeutics: successes and complications	18
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	18
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	17
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	17
Dynamics of biological markets with multiple biosimilar competitors in the United States	17
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	16
The nail in psoriatic arthritis: new insights into prognosis and treatment	16
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	16
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	16
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	15
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	15
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	14
Emerging strategies for the prevention and management of chronic graft-versus-host disease	14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	14
Management of proctitis in ulcerative colitis and the place of biological therapies	14
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
Emerging peptide-based technology for biofilm control	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	13
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	12
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	12
Tarlatamab for small-cell lung cancer	12
An evaluation of pozelimab for the treatment of CHAPLE disease	12
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	12
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	12
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Belimumab patient profile in Spain: evolution during the last decade and future directions	11

Tremelimumab for the treatment of hepatocellular carcinoma	11
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	11
Biosimilars in osteoporosis treatment: focus on denosumab	11
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression	11
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	11
Recent developments and future clinical prospects of polyclonal antibody therapies	11
Treating psoriasis in the elderly: biologics and small molecules	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Correction	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
Epcoritamab in B-cell malignancies: current status and prospects	10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	10
Non-traditional approaches for control of antibiotic resistance	10
The role of monoclonal antibodies in the treatment of lupus nephritis	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	10
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Clinical management and innovation in fracture non-union	10
Current status and future potential of CD123-based targeted therapies for acute leukemia	9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	9
Correction	9
Sargramostim in acute radiation syndrome	9
X-linked myotubular myopathy: an untreated treatable disease	8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	8
Biologics in rectal cancer	8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	8
Advances in the management of giant cell arteritis–aortitis: biologic therapies and beyond - a narrative review	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
Antibody therapeutics for epithelial ovarian cancer	8
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives	8
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	8
Ravulizumab for the treatment of myasthenia gravis	8
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	8
Expression of Concern:	8
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	7
The future of interleukin gene therapy in head and neck cancers	7
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	7
Monoclonal antibodies in the management of hereditary angioedema	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
The future of cancer vaccines against colorectal cancer	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Belantamab mafodotin in multiple myeloma	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	7
CAR T cells for solid tumors – developments to watch in 2023	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7